A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2016
At a glance
- Drugs Vismodegib (Primary)
- Indications Medulloblastoma
- Focus Therapeutic Use
- 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2013 as reported by ClinicalTrials.gov record.
- 02 Jan 2013 Planned End Date changed from 1 Aug 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.